1h Free Analyst Time
The pulmonary arterial hypertension (PAH) drugs market is forecasted to grow by USD 2.26 billion during 2023-2028, accelerating at a CAGR of 6.78% during the forecast period. The report on the pulmonary arterial hypertension (PAH) drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by growing prevalence of PAH, growing geriatric population, and increasing risk factors for cardiovascular diseases.
The pulmonary arterial hypertension (PAH) drugs market is segmented as below:
By Route Of Administration
- Oral
- Injectable
- Inhalation
By Action Mechanism
- Prostacyclin analogs
- Endothelin receptor antagonists (ERAs)
- Phosphodiesterase (PDE) inhibitors
- Soluble guanylate cyclase stimulators (SGCSs)
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the pulmonary arterial hypertension (PAH) drugs market covers the following areas:
- Pulmonary arterial hypertension (PAH) drugs market sizing
- Pulmonary arterial hypertension (PAH) drugs market forecast
- Pulmonary arterial hypertension (PAH) drugs market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Route of Administration
7 Market Segmentation by Action Mechanism
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
360 degree market analysis
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global pulmonary arterial hypertension (PAH) drugs market: Aerami Therapeutics Holdings Inc., Aerovate Therapeutics Inc., Alembic Pharmaceuticals Ltd., Asklepion Pharmaceuticals LLC, AstraZeneca PLC, Bayer AG, Daiichi Sankyo Co. Ltd., DR Reddys Laboratories Ltd., Eiger BioPharmaceuticals Inc., Gilead Sciences Inc., GlaxoSmithKline PLC, Johnson and Johnson Services Inc., Lupin Ltd., Merck and Co. Inc., Novartis AG, Pfizer Inc., Reata Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., United Therapeutics Corp., and Viatris Inc..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is increasing awareness regarding PAH."
According to the report, one of the major drivers for this market is the growing prevalence of PAH.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Aerami Therapeutics Holdings Inc.
- Aerovate Therapeutics Inc.
- Alembic Pharmaceuticals Ltd.
- Asklepion Pharmaceuticals LLC
- AstraZeneca Plc
- Bayer AG
- Daiichi Sankyo Co. Ltd.
- Dr Reddys Laboratories Ltd.
- Eiger BioPharmaceuticals Inc.
- Gilead Sciences Inc.
- GlaxoSmithKline Plc
- Johnson and Johnson Services Inc.
- Lupin Ltd.
- Merck and Co. Inc.
- Novartis AG
- Pfizer Inc.
- Reata Pharmaceuticals Inc.
- Teva Pharmaceutical Industries Ltd.
- United Therapeutics Corp.
- Viatris Inc.
